Skip to main content

Table 3 Treatment and survival analysis of patients with paraproteinemia and renal damage

From: Clinicopathological characteristics of patients with paraproteinemia and renal damage

  MGRS (n  =  42) MM (n  =  14) MGUS (n  =  19) Renal monoIg (n  =  21) P value
Special treatment [n (%)] 36 (85.7) 13 (92.9) 13 (68.4) 18 (85.7) 0.239
Chemotherapy [n (%)] 19 (45.2)a,b,c 12 (85.7)d,e 0 (0) 0 (0) 0.000
Immunosuppression [n (%)] 12 (28.6)a,b,c 0 (0)d,e 12 (63.2) 18 (85.7) 0.000
Follow-up time (months) 47.6  ±  19.2 50.9  ±  18.4 38.9  ±  14.7 40.4  ±  10.0 0.080
Major response [n (%)] 10 (23.8)a,b,c 0 (0)d,e 11 (57.9)f 18 (85.7) 0.000
Partial response [n (%)] 16 (38.1) 6 (42.9) 5 (26.3) 3 (14.3) 0.185
ESRD [n (%)] 14 (33.3)b 8 (57.1)d,e 1(5.3) 0 (0) 0.025
Baseline eGFR (mL/min) 50.0 (14.7, 89.0) 15.6 (5.8, 34.7) 22 0.732
Renal survival time (months) 8.8  ±  10.0 9  ±  16.6 2 0.507
Death [n (%)] 7 (16.7)b,c 3 (21.4)d,e 0 (0) 0 (0) 0.014
Survival time (months) 9.4  ±  8.4 8.0  ±  6.1 0.651
  1. Baseline eGFR and renal survival time were of ESRD patients, while survival time was of died patients
  2. Special treatments included chemotherapy, immunosuppression, and renal replacement (including long-term dialysis and renal transplantation). Chemotherapy regimens consisted mostly of bortezomib combined with dexamethasone (BD regimen), thalidomide combined with dexamethasone (TD regimen), or vincristine and adriamycin combined with dexamethasone (VAD regimen). Immunosuppressive drugs consisted mainly of steroids, cyclophosphamide, mycophenolate mofetil, and rituximab
  3. ESRD end-stage renal disease, IS immunosuppression
  4. aP  <  0.05, MGRS vs MM group
  5. bP  <  0.05, MGRS vs MGUS group
  6. cP  <  0.05, MGRS vs renal monoIg group
  7. dP  <  0.05, MM vs MGUS group
  8. eP  <  0.05, MM vs renal monoIg group
  9. fP  <  0.05, MGUS vs renal monoIg group